Researchers have published the first description of the role of the ZFP36 family of RNA binding proteins in regulatory T cells (Tregs). Tregs are key to maintaining balance in the immune system and ...
COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
The gross proceeds to the Company from the private placement are expected to be approximately $11.1 million, before deducting offering expenses payable by the Company. No broker, placement agent or ...
Loosening chimeric antigen receptor's grip on T-regulatory cells improves function, researchers find
A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...
Lim et al. demonstrate that Treg cells deficient in PD-1 occupy key spatial niches within the TME, with regulatory subsets organized near tumor cells dampening anti-tumor immunity (red and dark blue ...
A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...
COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results